Relapsed or Refractory Mantle Cell Lymphoma (MCL) Archives

U.S. FDA Approves Kite’s Tecartus

Accelerated Approval, Approvals, CAR-T Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapies, FDA, FDA/Regulatory, Non-Hodgkin Lymphoma, Relapsed or Refractory Mantle Cell Lymphoma (MCL), T-Cells

The U.S. Food and Drug Administration granted accelerated approval to Gilead Company Kite’s Tecartus (brexucabtagene autoleucel, formerly KTE-X19) as the first approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

July 24, 2020/by Business Wire